20140723_QVOA_NIHAI2013184_Amend_3_FINAL.pdf

AMENDMENT #3, RFP NIAID-DAIDS-NIHAI2013184

Amendment No. 3

NIAID-DAIDS-NIHAI2013184

“Quantitative Viral Outgrowth Assay Service Resource”

Solicitation Number:

Amendment Number:

Amendment Issue Date:

NIAID-DAIDS-NIHAI2013184

Three (3)

July 23, 2014

Proposal Due Date/Time:

Thursday, August 14, 2014 at 3:00 PM, Local Time (Unchanged)

Issued By: Michelle L. Scala Contracting Officer

OA/DEA/NIAID/NIH/DHHS

6700-B Rockledge Drive, Room 3214 Bethesda, Maryland 20892-7612

Points of Contact: PRIMARY:

george.keane@nih.gov George Keane, Contract Specialist Phone: 301-451-3690

SECONDARY:

mscala@niaid.nih.gov Michelle L. Scala, Contracting Officer Phone: 301-451-3693

Please note that we do NOT intend to extend the due date for submission of proposals as a result of this amendment. The date specified for receipt of proposals remains unchanged.

The purpose of this amendment is to answer questions from potential offerors regarding the solicitation.

Offerors must acknowledge receipt of this amendment by identifying this amendment number and date of the amendment on each copy of the proposal submitted. Failure to receive your acknowledgement may result in the rejection of your proposal. Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

mailto:george.keane@nih.gov mailto:anhughes@niaid.nih.gov

AMENDMENT #3, RFP NIAID-DAIDS-NIHAI2013184

Questions from Potential Offerors:

Question 1:

For performance of the QVOA Assay, how many samples should be assumed for costing purposes?

Response to Question 1:

150-200 per year (see Attachment 5, Additional Business Proposal Instructions, page 2, section 3)

Question 2:

Will the contractor be required to provide healthy human blood to generate CD4+ lymphoblasts?

Response to Question 2:

Yes

Question 3:

Will the QVOA and any selected alternative assay(s) need to be qualified, validated, and/or GCLP qualified?

Response to Question 3:

We are asking for a laboratory-based assay system that is reliable and reproducible. The SOW states that the contractor will provide quality control procedures for all data generated under the contract such as scientific data, Contractor and subcontractor/consultant reports, etc. We are expecting standard quality control and assurance systems to be in place.

Question 4:

For the development of alternatives to the QVOA, can we propose 3.5 FTEs per assay being developed?

Response to Question 4:

The entire number of FTE’s in the base contract per year is 3.5. Developing an alternative assay would have to be achieved using that number of FTE’s. If all FTE’s were used in assay development during a particular year, nothing else (requiring effort) could be done. A total of

1.65 additional FTE’s would be available per year should all three options for increased services be exercised. However these FTE’s are for doing more assays, not developing an alternative assay.